It sounds academic until you realize most commercialization problems trace back to companies misunderstanding which category they’re actually operating in.

The safest place in medtech is the “known known.” Known problem. Known solution. Feeding tubes, Foley catheters, standard procedural tools—products hospitals already buy, clinicians already understand, and procurement systems already accommodate. In these categories, commercialization is mostly an exercise in incremental improvement: make it cheaper, slightly better, or operationally easier than the incumbent product. Even the regulatory pathway is usually more predictable, often involving Class I exemption or a relatively straightforward 510(k).

Not particularly exciting. Also not particularly risky.

The industry likes to romanticize disruption, but healthcare systems are structurally designed to reward familiarity.

The harder category is the “known unknown”: a recognized clinical problem without an established or broadly accepted solution. This is where commercialization stops being about engineering and starts becoming about institutional persuasion.

A useful example is nasogastric tube placement verification. For years, clinicians commonly relied on auscultation—injecting air and listening for sounds—to confirm placement. The issue, of course, was that misplaced tubes entering the lungs instead of the stomach could produce catastrophic outcomes, including fatal feeding complications. But because patient deaths were often documented under broader causes like cardiac arrest, the underlying problem remained partially obscured within the system itself.

Healthcare responds slowly to problems it cannot clearly quantify.

The eventual pH-based bedside verification device still had to navigate both FDA clearance and CLIA-waived requirements for bedside use. Yet the regulatory process was only part of the challenge. The longer effort involved educating clinicians, influencing practice standards, and convincing hospitals that a familiar workflow was no longer acceptable.

That timeline reportedly stretched close to 18 years before broader adoption gained traction.

Eighteen years is long enough for a startup to discover that “market readiness” and “clinical need” are not interchangeable concepts.

Then there’s the category many early-stage companies accidentally drift into: unknown problem, known solution. This is where elegant technology starts searching for clinical relevance after development is already underway. It happens frequently in founder-led innovation and university spinouts, where a highly specific frustration inside one practice environment gets interpreted as widespread market demand.

The technology itself may be excellent. The problem is that hospitals do not reorganize themselves around elegance.

Healthcare systems are governed by reimbursement pressures, workflow constraints, staffing shortages, liability concerns, purchasing committees, accreditation standards, and institutional habit. A device can be objectively safer or more sophisticated and still lose commercially because the current workaround is perceived as “good enough.”

Especially when the existing process feels operationally free.

That’s the uncomfortable reality behind many commercialization failures in medtech: the FDA is rarely the only gatekeeper that matters. Regulatory clearance determines whether a product can legally enter the market. It does not determine whether the market is psychologically, operationally, or financially prepared to change behavior.

The companies that succeed tend to understand this early. They recognize that commercialization is not just about solving clinical problems—it’s about correctly identifying whether the healthcare system already agrees the problem exists in the first place.

1. “State of the art” is an interpretive and strategic concept, not simply a technology benchmark.
   Regulators increasingly expect manufacturers to justify devices against accepted medical practice, alternative therapies, real-world clinical use, and evolving standards of care—not just technical innovation.

2. Regulatory unpredictability is becoming a business risk in itself.
   Inconsistent interpretations, shifting reviewer expectations, and expanding evidence demands are forcing medtech CEOs to treat regulatory strategy and risk management as executive-level commercial functions rather than back-office compliance activities

3. Risk management is no longer just a regulatory requirement—it directly impacts commercialization.
   Under the EU MDR, the risk management file influences market access, review timelines, clinical positioning, and even which geography companies choose to enter first.

There’s a moment in every medtech company’s lifecycle when leadership realizes the risk management file is no longer just a regulatory document.

It’s the business strategy.

Under the EU MDR, regulators and notified bodies increasingly use risk management as evidence that a manufacturer truly understands the clinical reality surrounding its device—not just the engineering. That shift is quietly reshaping commercialization timelines, clinical strategy, and even market selection.

The problem is that the European system itself does not operate with a single interpretive voice. The European Commission writes legislation. National competent authorities enforce it. Notified bodies assess conformity. Standards committees define technical expectations. Everyone is pursuing patient safety, but not always with the same interpretation.

That matters because MDR compliance increasingly depends on interpretation rather than straightforward regulatory clarity. The result is what manufacturers are experiencing now: inconsistent reviewer expectations, repeated requests for additional clinical justification, prolonged review cycles, and growing uncertainty around what qualifies as sufficient evidence.

Much of the confusion centers on the phrase “state of the art.”

Most executives hear that term and think “most advanced technology available.” ISO 14971:2019 does not. The standard defines state of the art as generally accepted good practice in medicine and technology and explicitly states that it does not necessarily mean the most technologically advanced solution.

That distinction changes the entire conversation.

Regulators are no longer simply asking whether a device is innovative. They are asking whether the manufacturer can justify its design choices, controls, usability profile, and clinical positioning relative to accepted medical and technological practice.

Complicating matters further, MDR often blends technical “state of the art” with clinical “standard of care” without clearly separating the two. And standard of care is not universal. It varies by geography, infrastructure, physician practice patterns, and patient population.

That is why risk management has evolved into a proxy for clinical credibility.

Manufacturers are increasingly expected to account for alternative therapies, evolving clinical guidelines, patient subgroups, contraindications, and real-world use conditions—not just competing devices. In practice, that means the comparison set may include surgery, pharmaceuticals, or entirely different approaches to care.

Meanwhile, reviewer turnover inside notified bodies is compounding the problem. Companies can cycle through multiple reviewers during a single submission, with each effectively resetting expectations. At some point, evidence generation stops being about clinical understanding and starts becoming an exercise in reducing reviewer uncertainty.

That becomes expensive fast.

The clearest signal that the landscape has changed is strategic: many companies now view the FDA pathway as more predictable than MDR certification. Europe was once the preferred first-market pathway. Increasingly, it is not.

For CEOs, this is no longer a regulatory operations issue. It is a capital allocation issue.

The companies navigating this environment best are not necessarily the ones with the largest regulatory teams. They are the ones treating risk management as an executive-level commercial function tied directly to market access, clinical positioning, and long-term growth.

Because under MDR, the risk management file is no longer documenting the business.

It’s increasingly determining whether the business gets to exist at all.